AAPG (AAPG) Stock Price & Analysis
AAPG (AAPG) rose 0.00% to USD 17.07 as of June 11, 2026 at 03:34 UTC, according to Nexqual real-time market data.
AAPG last closed at USD 17.07; the session ranged USD 17.07–17.07 on volume of 1,507 shares. Market capitalization is $1.59B, with a 52-week range of USD 16.92–48.45 (NGM). Source: Nexqual, June 11, 2026 at 03:34 UTC.
Key Statistics (as of June 11, 2026 at 03:34 UTC)
| Price | USD 17.07 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 17.07 |
| Open | USD 17.14 |
| Day Range | USD 17.07 – 17.07 |
| 52-Week Range | USD 16.92 – 48.45 |
| Volume | 1,507 shares |
| Market Cap | $1.59B |
| Exchange | NGM |
Technical Analysis (AAPG)
Nexqual's technical model rates AAPG "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 11, 2026 at 03:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.44 (oversold) |
| vs SMA50 | Below (USD 22.44) |
| MACD | -1.34 (negative) |
Analyst Ratings (AAPG)
Wall Street analysts rate AAPG "Strong Buy" based on 8 analysts, with a mean price target of USD 47.88 (range USD 40–55), per Nexqual as of June 11, 2026 at 03:34 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 47.88 |
| High Target | USD 55 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (AAPG)
| Next Earnings Date | 2026-03-25 |
|---|---|
| EPS Estimate | USD -0.58 |
| Revenue Estimate | $132.29M |
Source: Nexqual, June 11, 2026 at 03:34 UTC.
Financials & Fundamentals (AAPG)
| Total Revenue | $574.12M |
|---|---|
| Revenue Growth (YoY) | +117.00% |
| Gross Margin | +91.48% |
| Operating Margin | -193.35% |
| Profit Margin | -216.47% |
| ROE | -154.56% |
| Debt / Equity | 148.38 |
| Current Ratio | 1.79 |
| Total Cash | $2.47B |
| Total Debt | $1.98B |
| Free Cash Flow | $-942.63M |
Source: Nexqual, June 11, 2026 at 03:34 UTC.
Financial Health Score (AAPG)
Nexqual rates AAPG's overall financial health "Weak" across five dimensions, as of June 11, 2026 at 03:34 UTC.
| Growth | Critical — Revenue -41% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $2.47B cash vs $1.98B debt, net cash position |
| Cash Flow | Weak — FCF negative: -$943M, burning cash |
| Efficiency | Critical — ROE -155%, ROA -23.0% |
Ownership (AAPG)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.06% |
| Shares Outstanding | 93.34M |
| Float | 55.71M |
| Short % of Float | +0.00% |
Source: Nexqual, June 11, 2026 at 03:34 UTC.
Leadership (AAPG)
AAPG is led by Dajun Yang (age 62), Co-Founder, Chairman & CEO, per Nexqual as of June 11, 2026 at 03:34 UTC.
| Co-Founder, Chairman & CEO | Dajun Yang (age 62) |
|---|---|
| Co-Founder, Chief Scientific Advisor & Non-Executive Director | Shaomeng Wang (age 60) |
| Chief Financial Officer | Veet Misra |
| Senior Director of Investor Relations | Yuly Chen |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | USD 3.48 | ▼ 3.06% |
| SION | Sionna Therapeutics, Inc. | USD 34.03 | ▲ 1.55% |
| MAZE | Maze Therapeutics, Inc. | USD 23.66 | ▲ 0.34% |
| AVBP | ArriVent BioPharma, Inc. | USD 30.49 | ▼ 0.03% |
| BCAX | Bicara Therapeutics Inc. | USD 20.21 | ▲ 0.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 03:34 UTC. This page is informational and not investment advice.